pyrazines has been researched along with Esophageal Reflux in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, K; Antonsson, M; Broddefalk, J; Jensen, J; Jin, S; Lehmann, A; Nilsson, K; Plowright, AT; St-Onge, S; Tomaszewski, MJ; Tremblay, M; Ulander, J; Walpole, C; Wei, Z; Yang, H | 1 |
1 other study(ies) available for pyrazines and Esophageal Reflux
| Article | Year |
|---|---|
Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.
Topics: Administration, Oral; Animals; Aryl Hydrocarbon Hydroxylases; Benzamides; Biological Availability; Brain; Cell Line; Cricetinae; Cricetulus; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dogs; ERG1 Potassium Channel; Esophageal Sphincter, Lower; Ether-A-Go-Go Potassium Channels; Gastroesophageal Reflux; High-Throughput Screening Assays; Humans; Muscle Relaxation; Pyrazines; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Solubility; Structure-Activity Relationship; Sulfoxides; Triazoles | 2013 |